<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1608">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04388813</url>
  </required_header>
  <id_info>
    <org_study_id>102293</org_study_id>
    <nct_id>NCT04388813</nct_id>
  </id_info>
  <brief_title>Predictors of Severe COVID-19 Outcomes</brief_title>
  <acronym>PRESCO</acronym>
  <official_title>Predictors of Severe COVID-19 Outcomes (PRESCO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Verily Life Sciences LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Verily Life Sciences LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a longitudinal, multi-center, observational study collecting diverse biological
      measurements and clinical and epidemiological data for the purpose of enabling a greater
      understanding of the onset of severe outcomes, primarily acute respiratory distress syndrome
      (ARDS) and/or mortality, in patients presenting to the hospital with suspicion or diagnosis
      of COVID-19. We seek to understand whether there are early signatures that predict
      progression to ARDS, mortality, and/or other comorbid conditions. The duration of the study
      participation is approximately 3 months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 28, 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Performance (discrimination / calibration) of models</measure>
    <time_frame>From date of study enrollment until the date of first documented ARDS diagnosis or date of death from any cause, whichever comes first, assessed up to study end (estimated at 3 months).</time_frame>
    <description>Performance (discrimination / calibration) of models that predict the risk of development of ARDS and/or mortality among COVID-19 patients who present to the hospital for evaluation and treatment.</description>
  </primary_outcome>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <condition>COVID-19</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Participants confirmed positive for COVID-19.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant or legally authorized representative willing and able to provide informed
             consent

          -  Receiving care at a participating site

          -  Age 18 years old or older

          -  U.S. Resident

          -  Confirmed positive for COVID-19

          -  Willing and able to comply with all study procedures

        Exclusion Criteria:

          -  Self reported pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charlie Kim, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Verily Life Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Marks, MD</last_name>
    <role>Study Director</role>
    <affiliation>Verily Life Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leera Choi</last_name>
    <phone>650-880-5106</phone>
    <email>leerac@verily.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Castro</last_name>
      <phone>312-413-3291</phone>
      <email>lschra3@UIC.EDU</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Moy, MD</last_name>
      <phone>312-942-6176</phone>
      <email>jmoy@rush.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inova Health Care Services</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Garofalo</last_name>
      <phone>703-776-2018</phone>
      <email>Stephanie.Garofalo@inova.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>May 4, 2020</study_first_submitted>
  <study_first_submitted_qc>May 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2020</study_first_posted>
  <last_update_submitted>August 17, 2020</last_update_submitted>
  <last_update_submitted_qc>August 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

